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ABSTRACT  
 
 
OBJECTIVE:  The objective of this selective EBM review is the determine whether or not, “oral 
steroids are as effective as NSAIDS in relieving patient pain from gout?” 
 
STUDY DESIGN:  Review of three English language primary studies, published between 2008 
and 2016. 
 
DATA SOURCES: Three randomized controlled trials (RCTs) were found using PubMed and 
Embase database. These studies analyzed the effectiveness of steroids in relieving patient pain 
from gout.  
 
OUTCOMES MEASURED:  The major outcomes measured were improvements in joint 
tenderness on palpation, joint erythema, joint swelling, and joint activity measured on a 5-point 
Likert scale. (0=no pain, 1=mild pain, 2=moderate pain, 3=severe pain, 4=extreme pain). 
Analgesic effectiveness was measured as changes in pain on a 100-mm visual analogue scale. 
With 1 being the least pain the patient has ever experiences and 100 being the worst.  
 
RESULTS: All three studies showed comparable efficacy between prednisolone and NSAIDS in 
treating gout. The Xu et al study concluded similar results between NSAIDS and Prednisolone in 
improving pain, tenderness, and joint activity. Furthermore, the study also stated Prednisolone 
may be more effective in reducing inflammation and was better tolerated. The Rainer et al and 
Janssen et al study found prednisolone and indomethacin have similar analgesic effectiveness, 
and prednisolone is a safe, and effective first line option for gout treatment.  
 
CONCLUSION: The results of all three RCT’s which compared the efficacy between 
prednisolone and NSAIDS in the treatment of gout concluded similar results between the two 
groups. Therefore, proving steroids as an effective treatment option for patients diagnosed with 
gout.  
 
KEY WORDS: Gout, Steroids, and NSAIDS. 
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INTRODUCTION 
 
 Gout is a metabolic disease associated with abnormal amounts of urates which manifests 
as recurrent acute arthritis. 5 The disease will most commonly present in the first metatarsal 
phalangeal joint of the great toe also known as “podagra”.5 Areas such as the feet, ankles, and 
knees, are also commonly affected.5 The attacks are characterized by intense pain with swollen, 
warm, and tender joints, dusky red skin overlying the joint space, and fever.5 In some cases tophi 
can be found on the feet, ears, and hands as a result of accumulation of uric acid crystallization 
years after the initial gout attack.5 Purine rich foods are proven to potentiate attacks such as 
alcohol, seafood, and thiazide diuretics.5 Patients may be asymptomatic for months or even years 
after their first attack. However, if left untreated patients can develop chronic gout.5 This paper 
discusses the results of three randomized control trials to determine if steroids are indeed as 
effective as NSAIDS in treating patients diagnosed with gout. 
 This topic is relevant to both patients and the PA practice because gout is the most 
common form of inflammatory arthritis.5 Gout most commonly effects men over the age of 30 
years old.5 When gout manifests in women it most commonly appears after the woman is 
postmenopausal.5 It is crucial as medical professionals we accurately diagnose and treat gout, 
because if left untreated patients can develop chronic gout which can lead to deformation of the 
joint spaces mimicking the effects of rheumatoid arthritis.5  As a result, these patients are at an 
increased risk for joint replacements and corrective surgeries.1 
 Due to the rising frequency and widespread occurrence of gout there is an increased cost 
burden associated with the disease.1 For patients who suffer six or more gout flares per year, 
direct gout-related health care costs top $12,020.4  Furthermore, according to a 2016 study, gout 
hospitalization expenses have increased by 68% from 34,456 to 58,000.4 There is an increasing 
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number of patients who visit their healthcare provider due to gout attacks each year.4 According 
to the “National Ambulatory Survey” between the years of 2008 and 2016, there were 7 million 
ambulatory visits due to gout.1 Therefore, there is an overwhelming need in the medical 
community to correctly diagnose, treat, and care for patients diagnosed with gout to decrease the 
economic burden surrounding the disease.4 
 Gout is widely understood throughout the medical community as uric acid deposition in 
the soft tissue as well as bone and joints.5  However, the amount of uric acid present in the serum 
does not depict the severity of the disease.5  Furthermore, the precise relationship between 
hyperuricemia and gouty arthritis is still unknown.5  This is because chronic hyperuricemia is 
found in those who have never before experienced a gout attack.5 Instead, medical professionals 
rely on arthrocentesis, as the test of choice when diagnosing patients with acute gout.5 The fluid 
will show negatively birefringent needle shaped crystals under a light microscopy which 
differentiate gout from pseudogout.5 
 Treatment of gout begins with lifestyle modifications such as a decrease in intake of 
purine rich food such as alcohol, seafood, and red meat.5  It is also crucial to consider 
medications such as loop and thiazide diuretics which can potentially increase serum uric acid 
levels and provoke gout attacks.5 NSAIDS such an Indomethacin are currently used as the drug 
of choice in acute gout attacks.5 Colchicine is considered 2nd line if the patient presents within 36 
hours of onset or are refractory to the use of NSAIDS.5  Steroids are then considered if the 
patient is unresponsive to both NSAIDS and Colchicine.5  It is important to treat episodes of 
acute gout and chronic gout differently as medications to treat chronic gout can potentiate or 
worsen gout symptoms if given during an acute gouty episode.5 Drugs such as Allopurinol which 
reduces uric acid production or Probenecid which promote renal uric acid secretion are available 
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to treat patients with recurrent or chronic gout.5  Each treatment listed above has shown to be 
beneficial for patients suffering from gout. Treatment is based on patient presentation, time-
period, and past medical history. In addition, based on the three articles, steroids are proven to be 
just as effective as NSAIDS as first line treatment for gouty arthritis.  
OBJECTIVE 
The objective of this selective EBM review is the determine whether or not, “oral steroids 
are as effective as NSAIDS in relieving patient pain from gout?” 
METHODS 
The population analyzed in this review includes patients diagnosed with gout. One group 
was given Prednisone in comparison to the other group which received a trial of NSAIDS. The 
outcome studied in these reviews is pain relief, and the patients rated their amount of pain 
through a Likert or visual analogue scale. All three studies are randomized controlled trials 
which studied the effectiveness of Prednisolone in comparison to NSAIDS.  
All three studies were published in peer reviewed English articles. The key words used to 
locate the articles included “gout”, “steroids”, and “NSAIDS”, and were searched on the Pubmed 
and Embase databases.  The articles were chosen based on relevance to the clinical question, and 
due to importance to the patient population in order to create a POEM. A POEM stands for 
patient-oriented evidence that matters.  Inclusion criteria included all randomized controlled 
trials published after 2001. Exclusion criteria included patients who used NSAIDS or steroids 
24-72 hours prior, had progressed to the chronic gouty arthritis stage, or had been diagnosed with 
gastrointestinal disease. The statistics reported in all three studies included confidence interval, 
p-value and mean change from baseline. Each of the three studies demographics and 
characteristics can be found on Table 1. 
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Results: Table of demographics and characteristics of included studies (Table 1) 
 
Study  Type  # Pts Age 
(yrs) 
Inclusion 
Criteria  
Exclusion 
Criteria 
W/D Interventions  
Janssens, 
2008 (1) 
RCT 120 All ages Pts with 
monoarticular 
gout 
confirmed by 
arthrocentesis. 
Pts were 
required to 
give consent. 
Pts with 
comorbidities 
such as renal 
failure or heart 
attack. Pts with 
history of GI 
disease. Pts 
were not 
allowed to have 
NSAIDs or 
other pain meds 
24 hours prior.   
1 Prednisolone  
Rainer, 
2016 (2) 
RCT 416 Pts aged 
18 years 
or older 
Pts who 
presented to 
the ER within 
3 days of 
symptom 
onset. Pts 
were 
evaluated by a 
physician to 
be diagnosed 
with gout. 
Pts were not 
allowed to 
receive steroids 
or NSAIDs 
within 24 hours.  
Pts with hx of 
comorbidities, 
suspected septic 
arthritis or 
history of 
bleeding 
disorders.  
40 Prednisolone  
Lingling 
Xu, 2015 
(3) 
RCT 132 Pts aged 
18 years 
and 
older 
Pts who 
presented 
with gout 
attacks within 
72 hours of 
screening. 
The degree of 
pain on the 
Likert scale 
was at least 
moderate.  
Pts were 
excluded if they 
had chronic 
gouty arthritis, 
clinical 
suspicion of 
joint disease, 
comorbidities, 
GI issues, 
NSAIDS or 
steroids within 
72 hours. 
19 Prednisolone  
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OUTCOMES MEASURED 
 All three studies measured the outcome of pain relief through either a 5-point Likert scale 
or visual analog scale. The Xu et al study primarily focused on the reduction of pain as 
experienced by the patient.7 The degree of joint pain was represented by a 5-point Likert scale 
(0=no pain, 2=moderate pain, 3=severe pain, 4=extreme pain).7 The number was then recorded 
by the patient on day 1 before the start of treatment and on day 2 and 4 approximately 4 hours 
after the dose of drug was administered.7 The physician also measured the patient’s overall 
response to treatment on a 5- point Likert scale (0=very good, 1=good, 2=fair, 3=poor, 4=very 
poor) at day 4 at the end of the study.7 Although the study also analyzed joint tenderness to 
palpation, joint erythema, joint swelling, and joint activity, for the purpose of study only pain 
scores were analyzed.7 The remaining two studies measured analgesic effectiveness as changes 
in pain on a visual analogue scale with 1 being the least amount of pain the patient has ever 
experienced to 100 being the worst.  
RESULTS 
All three studies included in this paper are randomized control trials studying the 
effectiveness of Prednisolone in comparison to NSAIDS in the treatment of gout. Although each 
study implemented different participant age requirements, all patients were included if they were 
diagnosed with acute gouty arthritis. All studies presented data in continuous format and no 
dichotomous data was converted. Changes in mean score, confidence interval, and p-value with a 
significance of  0.05 was analyzed. 
In the Xu et al study, 132 inpatients aged 18 or older with acute gouty arthritis within 72 
hours of onset were randomly assigned to trial treatments.7 These patients were diagnosed with 
gout according to the clinical criteria of the 1977 American College of Rheumatology 
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classification.7 The participants were chosen based on the inclusion and exclusion criteria listed 
in Table 1. The patients were randomly assigned using computer-generated tables and prepared 
by an independent party.7 The participants received either Prednisolone 35 mg qd, Etoricoxib 
120 mg qd, or Indomethacin 50 mg tid. 7 The patients were only studied for 4 days due to the 
self-limiting nature of acute gouty arthritis.7 The participants pain levels were measured using a 
5-point Likert scale and the same physician observed and studied each patient throughout the 4 
days.7 Of the 132 patients who were randomized, 113 participants were ultimately analyzed. Of 
the 113 studied, 33 were given Prednisolone, 44 were given Etoricoxib, and 36 were given 
Indomethacin.7 Adverse effects noted during the trial mainly included gastric or abdominal pain, 
dizziness, edema, fatigue, drowsiness, and dry mouth.7   
The results demonstrate both Indomethacin and Prednisolone significantly decrease the 
severity and pain of acute gouty arthritis. The mean difference between the two groups is 0.11 
with a p value of 0.416.7 The treatment effect is small. This is because the reduction in pain 
when comparing Prednisolone to Indomethacin is 0.11. The confidence interval is wide at 95% (-
0.16 to 0.39). 7 This is due to the small sample size.7 The p-value is 0.415.7 Therefore, because 
the p > 0.005 there is no significant difference between the groups.  The efficacy of Prednisone in 
reducing pain was comparable to Indomethacin after 4 days. Furthermore, there is no significant 
difference between the groups and Prednisolone can be used just as effectively to treat gout.  
Results: Indomethacin vs Prednisolone (Table 2) 
 
Group Value Measured LS Mean Difference Confidence Interval P Value 
Prednisolone 
vs 
Indomethacin 
Pain 0.11 (.0138) -0.16 to 0.39 0.415 
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In the Rainer et al double-blind randomized trial, 416 patients aged 18 years or older with 
a clinical diagnosis of acute gout were enrolled in the study.3 Of the 416 enrolled, 376 completed 
the study. 3 The patients were chosen based on the inclusion and exclusion criteria listed in table 
1. Patients were randomly assigned using a 1:1 ratio to receive either Indomethacin or 
Prednisolone for 5 days.3 The physicians and patients were unaware of which drug they were to 
receive. In the Indomethacin group (n=208), patients initially received 50mg (two 25mg tablets) 
of oral Indomethacin 3 times daily. 3 Patients were also given 6 tablets of oral placebo 
Prednisolone to take once daily for 2 days. 3 This was followed by 25 mg of Indomethacin 3 
times a day and the placebo Prednisolone to take once per day for 3 days.3 In the Prednisolone 
group (n=208), patients initially took 30 mg (three 10mg tablets) of oral Prednisolone once a 
day, and 2 tablets of placebo Indomethacin 3 times a day for 2 days.3  This was followed by 
30mg (three 10 mg tablets) of Prednisolone once a day and 1 tablet of placebo Indomethacin 3 
times a day for 3 days.3  Patients were required to take the first dose in the presence of one of the 
investigators and all patients were given the analgesic Acetaminophen to use as needed.3  The 
results were measured using a 100mm visual analogue scale.3  
When comparing the effectiveness of Indomethacin to Prednisolone in this study, there 
was a small difference between the two groups. While measuring decrease in pain scores on days 
1-14 while the patient was a rest, demonstrated a reduction of 1.67 mm for Indomethacin and 
1.52 mm for Prednisolone.3 As a result, the difference in mean pain score between the two 
groups is 0.15 mm.3 Furthermore, the number of patients which demonstrated a significant 
change in their pain score was calculated.3 Among the patients who received Indomethacin, 111 
patients illustrated a significant change, and in the Prednisolone group 101 patients demonstrated 
a change in pain score.3 Therefore, the average difference between the two  
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 groups are 10 (4.8%).3 Ultimately, when analyzing the small mean difference and p-value of 
0.92, which is clinically insignificant, indicates Prednisolone can be used as effectively as 
NSAIDS in the treatment of gout. 
Results: Indomethacin vs Prednisolone (Table 3) 
In the Janssens et al study, 120 patients were randomly assigned to trial treatments.2 
Between the months of March 24, 2004 and July 14th, 2006, family doctors were asked to send 
all patients with monoarthritis to the trial center. 2 These patients were sent even if gout was not 
the primary diagnosis, to minimize the risk of missing potential study participants.2 Patients were 
then assessed in the trial center for inclusion eligibility within day 1 after they visited their 
family doctor.2 Patients were separated randomly into two groups by computer generated 
randomization, and 60 patients were in each group. 2 Both the patients and the physicians were 
unware which group received Naproxen or Prednisolone.2 The first group received one 35 mg 
tablet of Prednisolone, and the other group received 500 mg of Naproxen which was taken twice 
a day. 2 The trial period lasted for 5 days.2 The results were measured on a 100mm visual 
analogue scale.2 The adverse effects recorded were similar to the Rainer study, and resolved 
within 3 weeks.2  
 This study further indicated the similar efficacy of Prednisolone in comparison to 
NSAIDS.2 Pain score was measured at baseline and at 90 hours. Pain score at baseline for 
Day 1-14 
At Rest 
Indomethacin  
N=208 
Prednisolone  
N=208 
Difference  P Value 
Mean Decrease in 
Pain Score (95% CI) 
1.67 (1.36 to 1.98) 1.52 (1.25 to 1.79)  0.15  0.92 
Patients with 
significant change in 
Pain Score 
N=111 N=101 10  
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Prednisolone was 61.5 mm, and 58.9 mm for Naproxen.2 After 90 hours, pain score for 
Prednisolone was 16.8 mm, and 12.9 mm for Naproxen.2 Therefore, patients who took 
Prednisolone had a pain decrease of 44.7mm, and those who took Naproxen had a decrease of 
46.0 mm.2 This equals a 1.3 mm overall difference between the two medications.2 The 
confidence interval is (-9.8 to 7.1). 2 The confidence interval is wide due to small sample size, 
however the small change in mean from baseline proves there is no significant difference 
between the groups.2 Adverse side effects included nausea, dizziness, and sleepiness. No major 
side effects were reported.2 
Results: Naproxen vs Prednisolone (Table 4) 
Prednisolone (n=59) Naproxen (n=59) 
Baseline: 61.5 Baseline: 58.9 
After 90 hr: 16.8 After 90 hr: 12.9 
Score Reduction: 44.7 Score Reduction: 46.0 
 
DISCUSSION 
 Due to the statistics presented above it is evident Prednisolone is as effective as NSAIDS 
in the treatment of acute gout. All three studies found a similar reduction in pain score between 
the steroid and NSAID group. Furthermore, the p-values calculated in the studies were clinically 
insignificant indicating both drugs can be used interchangeably. The Xu et al RCT claimed 
efficacy was comparable among Prednisolone, Etoricoxib, and Indomethacin in treating acute 
gout.7 However, Prednisolone might be more effective in reducing inflammation and was better 
tolerated.7 Furthermore, the Xu et al study found that patients experienced more total adverse 
events with Indomethacin compared to Prednisolone.7 The Rainer et al study claimed 
Prednisolone is a safe, effective first line treatment for acute gout. 3 Per current medication 
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guidelines, NSAIDS are the first line treatment option for patients presenting with acute gout. 
However, due to the data presented above it is reasonable to consider Prednisolone as an 
alternative first line treatment to NSIADs in treating gouty arthritis.  
 After reviewing the different methods and study designs it is apparent there were some 
limitations. Firstly, it is important to note the definitive diagnoses for acute gout is arthrocentesis 
where the fluid is analyzed to determine the diagnosis.5 However, only the Janssens et al study 
diagnosed patient gout with arthrocentesis. The other two studies only used clinical judgment to 
make a diagnosis. Therefore, it is uncertain that all patients in the studies without arthrocentesis 
had gout. This diagnostic uncertainty could have resulted in inaccurate data. Secondly, the 
sample sizes in each study were small. The Janssens et al and Xu et al both studied around 130 
patients, and the Rainer et al, analyzed around 400. Therefore, it is difficult to make large scale 
predictions on the data due to the small amount of the population represented in the studies. 
Thirdly, the time-period to which the patients were studied was relatively short. The Rainer et al 
RCT was the only study to analyze patients for over a week. The presentation of acute gout is 
limited and may only last for hours to a few short days. 5 Therefore, due to the limited nature of 
acute gout it is difficult to study it for a significant amount of time.  
 Prednisolone is a good and convenient treatment option due to its affordability, and 
accessibility.8 It is also crucial to provide patient education about the medication prescribed, and 
encourage each patient to finish their prescription to avoid relapses and unwanted medical costs.1 
Furthermore, most patients will be familiar with steroid medications and will feel comfortable 
taking their prescription.8 However, physicians do have their hesitations about steroids due to 
cushing’s syndrome, diabetes mellitus, hypertension, and osteoporosis.7 However, side effects 
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associated with NSAID use include gastrointestinal stomach pain, bleeding and peptic ulcers.7  
Furthermore, all medications will present potential risks and benefits.  
CONCLUSION    
The results of all three RCT indicate Prednisolone is just as effective as NSAIDS in the 
treatment of patients diagnosed with acute gout. Due to the increasing number of patients 
diagnosed with gout each year, it is important to consider different treatment options other than 
NSIADS to treat patient symptoms.1 It is also crucial to provide patient education about the 
medication prescribed, and encourage each patient to finish their prescription to avoid relapses 
and unwanted medical costs.1 If patients are not taking their medications as prescribed it is 
impossible to determine the efficacy of the medication. Furthermore, it is important all future 
studies consider and ensure patient compliance. It is imperative studies use arthrocentesis as a 
diagnosis requirement, as well as implement larger sample sizes to study different medication 
options. This would improve accuracy and credibility of each study. Lastly, it is important 
scientists and physicians continue to expand on treatment options for all patients, to successfully 
care and treat each individual patient diagnosed with acute gouty arthritis.  
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